Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rivoltan
- Development stage
- Unknown
- Lead developer
- Krewel Meuselbach
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rivoltan is a herbal pharmaceutical product developed and manufactured by Krewel Meuselbach. Its active ingredient is a dry extract derived from the root of Devil's Claw (*Harpagophytum procumbens*), with each film-coated tablet containing 480 mg of the extract. It is indicated for the supportive treatment of degenerative musculoskeletal disorders, including osteoarthritis, rheumatoid arthritis, and chronic back pain. The therapeutic effects are attributed to iridoid glycosides, such as harpagoside, which possess anti-inflammatory and analgesic properties. These compounds help reduce joint pain and improve mobility by inhibiting inflammatory mediators. Rivoltan is available as an over-the-counter (OTC) medication in Germany.
- Brand names
- RivoltanRivoltan Teufelskralle 480 mg
- Other names
- Harpagophytum procumbens root extractTeufelskrallenwurzel-TrockenextraktDevil's Claw root extract
02
Targets
ALOX5 (Arachidonate 5-lipoxygenase)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Rivoltan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rivoltan.